The financial terms of the agreement, which has an initial tenure of 10 years, were not disclosed.
Indian
drugmaker Sun
Pharmaceutical Industries Ltd said on Wednesday it would
introduce some of its cancer treatment drugs in China through
Britain's AstraZeneca.
This
comes after AstraZeneca
said it was launching a new fund with China International Capital
Corp to invest $1 billion in China's healthcare sector, as it expands
its research work in the country.
Sun
Pharma will be responsible for development, regulatory filings and
manufacturing of the drugs covered in the deal, while AstraZeneca
will exclusively promote and distribute the products in China,
according to a filing to Indian stock
The
financial terms of the agreement, which has an initial tenure of 10
years, were not disclosed.
Drug
major Sun Pharma on Saturday said it is discontinuing operations at
two clinical pharmacology units in Vadodara (Gujarat) to bring in
efficiencies in cost and processes.
"While
we continue to make investments in our R&D operations, we also
constantly evaluate our resources and future capacity requirements to
bring in efficiencies in cost and processes," a Sun
Pharmaceutical Industries spokesperson said in a statement.
To
ensure optimal utilisation of clinical pharmacology units (CPUs) that
conduct bio-equivalence studies, the company is discontinuing
operations at two centers at Tandalja and Akota in Vadodara, the
spokesperson added.
"The
bio-equivalence studies from these centers will be transferred to our
other facilities. We are offering full support to the affected
employees and helping them with out placement services," the
spokesperson said.
No comments:
Post a Comment